Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
40.69
-4.05 (-9.05%)
Sep 15, 2025, 3:02 PM EDT - Market open
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 15 analysts that cover Avidity Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $70.33, which forecasts a 72.84% increase in the stock price over the next year. The lowest target is $55 and the highest is $96.
Price Target: $70.33 (+72.84%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 8 |
| Buy | 6 | 6 | 7 | 7 | 8 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $56 → $65 | Strong Buy | Maintains | $56 → $65 | +59.74% | Sep 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $68 → $87 | Strong Buy | Maintains | $68 → $87 | +113.81% | Sep 12, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $65 | Strong Buy | Maintains | $60 → $65 | +59.74% | Sep 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $75 | Strong Buy | Maintains | $75 | +84.32% | Sep 10, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $75 | Buy | Maintains | $70 → $75 | +84.32% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
9.63M
from 10.90M
Decreased by -11.61%
Revenue Next Year
20.19M
from 9.63M
Increased by 109.60%
EPS This Year
-4.54
from -2.89
EPS Next Year
-5.10
from -4.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.8M | 68.7M | |||
| Avg | 9.6M | 20.2M | |||
| Low | 4.9M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.6% | 612.9% | |||
| Avg | -11.6% | 109.6% | |||
| Low | -55.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.50 | -3.43 | |||
| Avg | -4.54 | -5.10 | |||
| Low | -6.13 | -7.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.